ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1091

Mapping Monosodium Urate Crystal Deposition Within Joints in Tophaceous Gout: A Dual Energy CT Study

Chamaya De Silva1, César Díaz2, Gregory Gamble3, Anne Horne3, Anthony Doyle3, Lisa Stamp4 and Nicola Dalbeth3, 1Health NZ Waitemata, Auckland, New Zealand, 2Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 3University of Auckland, Auckland, New Zealand, 4University of Otago, Christchurch, Christchurch, New Zealand

Meeting: ACR Convergence 2024

Keywords: gout, Uric Acid, Urate

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: In gout, monosodium urate (MSU) crystal deposition occurs preferentially at certain joints, most frequently the first metatarsophalangeal (MTP) joint. Dual energy CT (DECT) allows visualization of MSU crystals. The aim of this DECT study was to map the distribution of MSU crystal deposition within the MTP joints in people with tophaceous gout. The study hypothesis was that MSU crystal deposition is evenly distributed within the joint in tophaceous gout.

Methods: Bilateral feet DECT scans of 124 people with tophaceous gout (57% male, mean disease duration 21 years, 98% on urate-lowering therapy, mean serum urate 6.9mg/dL) were analyzed. All participants met the ACR/EULAR 2015 classification criteria for gout. The metatarsal head and phalangeal base of each MTP joint was analyzed by dividing each bone into four quadrants (dorsal, plantar, medial, and lateral) as described by Pecherstorfer et al (ACR Open Rheumatology 2020). Each bone quadrant was scored for the presence or absence of MSU crystal deposition (eight sites per joint, 80 sites per participant). MSU crystal deposition was considered present if in contact with or directly adjacent (within 1mm) to bone or cartilage in at least two planes. All images were analyzed independently by two trained readers (inter-reader kappa 0.78 and percentage agreement 98.9%), and differences between readers was resolved by image review. Data was analyzed using general estimating equations undertaken to adjust for the likely closer agreement between bones in the same individual.

Results: There was marked variation in MSU crystal deposition across the analyzed sites (Figure). The medial quadrant of the 1st metatarsal head was most affected (57%) and significantly more affected than any other analyzed site. The next most common affected sites were the plantar quadrants of the 1st and 2nd metatarsal heads and medial quadrant of the 1st phalangeal base (all >30%). MSU crystal deposition was very rare in the phalangeal base of the 3rd and 4th MTP joints, particularly the lateral quadrants (1%). Across all joints, there was more MSU crystal deposition at the 1st MTP joint compared to other joints, at the metatarsal head compared to the phalangeal base, and at the plantar and medial quadrants compared to other quadrants (P< 0.001 for all comparisons). 

Conclusion: In people with tophaceous gout, MSU crystal deposition is not evenly distributed. There is marked lack of uniformity with preferential sites of deposition not only between different joints, but also within joints. Several biological mechanisms may explain these findings, including the influence of localized tissue planes, temperature or microtrauma.

Supporting image 1

Figure. Heatmap showing the percentage (95% CI) of participants with MSU crystal deposition. PB: phalangeal base, MH: metatarsal head.


Disclosures: C. De Silva: None; C. Díaz: None; G. Gamble: None; A. Horne: None; A. Doyle: None; L. Stamp: Uptodate, 9; N. Dalbeth: Arthrosi, 2, AstraZeneca, 5, 6, Avalo Therapeutics, 2, Dexcel Pharma, 2, Hikma, 6, Horizon, 2, 6, JPI, 2, JW Pharmaceutical Corporation, 2, LG Chem, 2, Novartis, 6, PK Med, 2, Protalix, 2, PTC Therapeutics, 2, Selecta, 2, Shanton Pharma, 2, Sobi, 2, Unlocked Labs, 2.

To cite this abstract in AMA style:

De Silva C, Díaz C, Gamble G, Horne A, Doyle A, Stamp L, Dalbeth N. Mapping Monosodium Urate Crystal Deposition Within Joints in Tophaceous Gout: A Dual Energy CT Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/mapping-monosodium-urate-crystal-deposition-within-joints-in-tophaceous-gout-a-dual-energy-ct-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mapping-monosodium-urate-crystal-deposition-within-joints-in-tophaceous-gout-a-dual-energy-ct-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology